Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VP 20621 for prevention of recurrent Clostridioides difficile infection
2010-020484-20Phase 2Completed
- Sponsor
- ViroPharma Incorporated
- Start
- Apr 2011
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing VP 20621 with Placebo (2 arms). Primary endpoints: Incidence of stool colonization with VP 20621 and Duration of stool colonization with VP 20621. Started Apr 2011; status: completed.
02
Drugs
nontoxigenic Clostridioides difficile strain M3
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2010-020484-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020484-20.